Four years after partnering with GammaDelta Therapeutics to develop therapies for solid tumors, Takeda Pharmaceutical pulled the trigger and exercised its option to acquire the London-based company.
If you are not happy with the results below please do another search
50 search results for:
An advisory panel of the U.S. Centers for Disease Control and Prevention will meet on Nov. 2 to discuss the use of Covid-19 vaccines in children aged between 5 and 11 years.
A new study shows the persistent syndrome of Covid-19 after-effects known as long Covid can develop after “breakthrough” infections in vaccinated people. Other new findings suggest a gene that helps the coronavirus reproduce itself might contribute to life-threatening Covid-19 in young, otherwise healthy people.
Covid-19 is slowly retreating across most of North, Central and South America, the Pan American Health Organization (PAHO) said on Oct. 27, reporting that last week the continent’s death and infection figures were the lowest in over a year.
Health and wellness advertising agency AbelsonTaylor promoted Beth Carik to senior vice president of human resources.
Eli Lilly and Pfizer announced Oct. 27 that they ceased the development of tanezumab, a pain drug the two companies had been developing for osteoarthritis.
Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.
Researchers at the Cleveland Clinic are set to launch a Phase I trial for what could be the first-ever vaccine to prevent triple-negative breast cancer.
Malvern, Pa.-based Ocugen submitted an Investigational New Drug Application to the U.S. Food and Drug Administration to run a Phase III trial of India’s Covid-19 vaccine BBV152 (Covaxin).
Angion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.